nmCRPC VL

Benefits of Early AR Targeting in Metastatic Hormone Sensitive Disease and nmCRPC - Karim Fizazi

Details
Karim Fizazi gives his insights into this evolving landscape of systemic therapies in both the non-metastatic castration-resistant and metastatic hormone-sensitive space. Dr. Fizazi discusses how therapies targeting the androgen receptor (AR) remains a critical focus in the treatment of prostate cancer. The data is showing that the introduction of these AR targeting drugs earlier in the course of...

Considerations for the Treatment of Non Metastatic Castration-Resistant Prostate Cancer - An Interview with Maha Hussain and Tia Higano

Details
Tia Higano and Maha Hussain share highlights of their 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentations with Alicia Morgans. Drs. Higano and Hussain presented opposing presentations on the pros and cons of treatment in the nonmetastatic castration-resistant prostate cancer setting. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in t...

Long-term Follow-up of Non-metastatic (M0) Patients in the STAMPEDE Randomized Trial - Interview with Nicholas James

Details
Nick James and Alicia Morgans talk about the newly presented STAMPEDE data just released and presented at the 2019 ESMO meeting including, long-term follow-up of the docetaxel patients as well as the much anticipated metastatic data. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR Senior Investigator, Consultant in Clinical Oncolo...

ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life - Karim Fizazi

Details
Karim Fizazi and Alicia Morgans discuss a follow-up on the quality of life parameters evaluated in the ARAMIS trial. Darolutamide was also associated with benefits with regard to all secondary end points, including overall survival, time to pain progression, time to cytotoxic chemotherapy, and time to a symptomatic skeletal-related event. The incidence of adverse events that occurred or worsened d...

Darolutamide Demonstrates Efficacy and Safety in Men with nmCRPC - Neeraj Agarwal

Details
Petros Grivas discussed Neeraj Agarwal's insights about the latest prostate cancer study results that will impact patient care as presented at ASCO GU 2019. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Darolutamide is a structurally unique androgen-receptor antagonist that is under develop...

ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC - Karim Fizazi

Details
Karim Fizazi discusses the efficacy and safety of darolutamide with Alicia Morgans. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer (nmCRPC). Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. In total, 1509 patien...

Delaying Disease Progression in Early Nonmetastatic CRPC Treatment - Fred Saad

Details
In this interview, Fred Saad reviews current and new agents showing benefit in the nonmetastatic castrate-resistant prostate cancer (nmCRPC) space and where the treatment paradigm stands in 2019 since data release in 2018. In addition, Fred makes the case for earlier treatment in nmCRPC patients and how targeting the androgen receptor is extremely effective which leads to better survival rates and...

Abiraterone Acetate for nmCRPC, The Forgotten Dance Partner? - Zach Klaassen and Chris Wallis

Details
Zach Klaassen and Chris Wallis discuss a jointly published paper that was published in Jama Oncology, November, titled, “Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer, The Forgotten Dance Partner?” They reference recent trials in this space and discuss cost and other variables to consider when making a therapeutic decision. Biographies: Zachary Klaassen, MD, MSc, Urolo...

IMAAGEN Trial: A Look into the Non-Metastatic Prostate Cancer Space - Charles Ryan

Details
(Length of Discussion: 20 min) Alicia Morgans and Charles Ryan have a dialogue on the study design, results and conclusions from the IMAAGEN trial in the non-metastatic prostate cancer space. The IMAAGEN trial evaluated the use of abiraterone acetate (1,000 mg) plus prednisone (5 mg) in patients with high risk, nonmetastatic, castration resistant prostate cancer. Biographies: Charles J. Ryan, MD A...

Comparison Between Surgery and Radiotherapy in the Treatment of Non-Metastatic Prostate Cancer- Christopher Wallis

Details
(Length of Presentation: 8 minutes) Christopher Wallis presents observational data from a large, population-based matched cohort demonstrating an association between treatment with radiotherapy vs radical prostatectomy and non-prostate cancer mortality. This controversial topic in urologic oncology is a usual subject of interest with respect to comparative effectiveness studies. In observational s...